2013-01-21 11:36:03 -
Orion Corporation Stock Exchange Release 21 January 2013 at
12.35 p.m. EET
The Nomination Committee of Orion Corporation has given on 21 January 2013 its
recommendation to the Board of Directors of the company for the proposal to the
Annual General Meeting of 2013 concerning the composition of the Board of
Directors to be elected. The Committee recommends that the following proposal be
presented to the AGM of 2013:
The number of Board members would be six.
The present Board members, Sirpa Jalkanen, Eero Karvonen, Timo Maasilta, Hannu
Syrjänen, Heikki Westerlund and Jukka Ylppö would be re-elected.
Hannu Syrjänen would be re-elected as Chairman.
The Nomination Committee also announces as its recommendation that the following
remunerations be paid to the Board of Directors:
annual fee, the Chairman would receive EUR 76,000, the Vice Chairman would
receive EUR 51,000 and the other members would receive EUR 38,000 each. As a fee
for each meeting attended, the Chairman would receive EUR 1,200, the Vice
Chairman would receive EUR 900 and the other members would receive EUR 600 each.
The travel expenses of the Board members would be paid in accordance with
previously adopted practice. The aforementioned fees would also be paid to the
Chairmen and to the members of the committees established by the Board, for each
committee meeting attended.
Of the annual fee, 60% would be paid in cash and 40% in Orion Corporation B-
shares, which would be acquired to the members during 25-28 March 2013 from the
stock exchange in amounts corresponding to EUR 30,400 for the Chairman, EUR
20,400 for the Vice Chairman and EUR 15,200 for each of the other members. The
part of the annual fee that is to be paid in cash corresponds to the approximate
sum necessary for the payment of the income taxes on the fees and would be paid
no later than 30 April 2013. The annual fees shall encompass the full term of
office of the Board of Directors.
The Nomination Committee has not given its recommendation for the remunerations
to the Board of Directors, but the matter will be proposed by a shareholder at
The Nomination Committee has consisted of the following members: Matti Kavetvuo,
Chairman, Kari Jussi Aho, Timo Ritakallio, Seppo Salonen, Hannu Syrjänen and
Timo Lappalainen Olli Huotari
President and CEO Senior Vice President, Corporate Functions
Matti Kavetvuo, Chairman of the Nomination Committee of Orion Corporation, phone
+358 50 5910744
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE